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similar. RESULTS: All programs apart from Connect were effective in improving CP. 
Comet showed significantly higher proportion of recovered cases than the biblio-
therapy (29.7% vs 17.4%) and higher costs. The CEA delivered an incremental cost-
effectiveness ratio for Comet versus bibliotherapy of US$8594 per one recovered case 
of CP. The cost-minimisation delivered an average cost per recovered case of US$585 
for the bibliotherapy, US$2445 for Cope and US$6624 for IY. CONCLUSIONS: In the 
absence of a willingness-to-pay threshold, bibliotherapy is the cheapest option to 
achieve minimal significant effects and could be a low-cost and easily delivered 
alternative within a limited budget. If decision-makers are willing to make larger 
investments Comet is the best alternative. Further studies are needed with longer 
follow-ups to ascertain on the sustainability of effects and a full economic evalua-
tion to help decision-makers set priorities across different interventions.
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OBJECTIVES: The aim of this study was to compare the cost-utility of hemodialysis 
(HD) and peritoneal dialysis (PD) as the initial modality of renal replacement therapy 
in Brazil. METHODS: We performed a retrospective cohort study using national 
administrative registries of all patients who began dialysis in 2000 through 2003 in 
Brazil. Propensity scores were calculated for the first treatment assignment from 
a large number of baseline covariates. The monthly expenditure per patient was 
estimated by summing all paid values extracted from the cohort. A utility measure 
was obtained from a nationwide observational cross-sectional study conducted in 
2007. The Markov model was utilized to estimate the life-years gained (LYG), quality 
adjusted life-years (QALY) and the projected costs for 10 years. The Brazilian Public 
Health System perspective was considered. RESULTS: Our cost-utility study dem-
onstrated superior performance of hemodialysis compared to peritoneal dialysis. 
As the initial modality, HD presented an incremental cost-effectiveness ratio (ICER) 
of US$ 14,833.05 per LYG; the incremental cost of PD was US$ 2,473.83. However, 
after 10 years, 92.5% of patients who started on HD and 95.8% who started on PD 
had died. CONCLUSIONS: Based on population data for the two methods currently 
used for the primary treatment of chronic kidney failure in Brazil, our analysis 
demonstrated that HD is superior to PD in terms of costs and QALY
PHS67
out-of-PoCket mediCal CoStS for ParentS witH CHildren witH down 
Syndrome in tHe united StateS
Kageleiry A.1, Samuelson D.1, Duh M.S.2, Lefebvre P.3, DerSarkissian M.4, Campbell J.Y.5, 
Skotko B.G.6
1Analysis Group, Boston, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Groupe d’analyse, 
ltée, Montreal, QC, Canada, 4Analysis Group, Los Angeles, CA, USA, 5Harvard University, 
Cambridge, MA, USA, 6Massachusetts General Hospital and Harvard Medical School, Boston, MA, 
USA
OBJECTIVES: Financial considerations may impact the pregnancy decisions of 
expectant parents who receive a positive prenatal screening test result for Down 
syndrome (DS). This study estimates the out-of-pocket health care costs for par-
ents associated with raising a child with DS between birth and 18 years of age, 
using private U.S. health insurance data. METHODS: Patients with a diagnosis of 
DS (ICD-9-CM 758.0x) who were enrolled in their family insurance plan as a child 
and had an identifiable parent were identified from the OptumHealth Reporting 
and Insights administrative claims database. A patient’s observation time was 
divided into clinically relevant age categories for DS. Patients with DS in each age 
category were matched to controls without diagnoses for chromosomal conditions. 
Mean annual health care utilization costs were compared between the patient-age 
cohorts with DS and matched controls using Wilcoxon signed-rank tests. RESULTS: 
After matching, patient-age cohorts were statistically similar with respect to most 
demographic and family characteristics. However, patients with DS had signifi-
cantly higher mean annual out-of-pocket costs than their matched controls within 
each age and cost category. Total annual incremental costs were highest among 
patients with DS from birth to age 1 ($1,907, p< 0.001), when the need for surgery 
is greatest. The greatest incremental costs were inpatient costs in the first year of 
life ($925, p < 0.001) and outpatient costs in later years (ranging from $623-$183, all 
p< 0.001). Overall, patients with DS incurred incremental out-of-pocket medical costs 
of $18,248 between birth and age 18 years. CONCLUSIONS: Across all age categories, 
mean total out-of-pocket annual costs for parents were greater among individuals 
with DS compared to their matched controls. On average, parents of children with 
DS pay an additional $84 per month for out-of-pocket medical expenses when costs 
are amortized over 18 years.
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OBJECTIVES: Individuals infected with hepatitis C (HCV) will transition through 
a series of disease stages over many years. This study estimates the incremental 
cost of direct medical care and health outcomes for a cohort of Albertans with 
HCV. METHODS: The study population was a closed cohort of 1190 persons (mean 
50 years) diagnosed with HCV in Alberta in 2012. We used a Markov model with one 
year cycles and an annual discount rate of 3% to estimate HCV-related costs and 
health outcomes over 10, 20, and 30 year time horizons. We used a health system 
perspective with screening and treatment costs included. Alberta data sources were 
used when available. Otherwise we used information from the literature. One-way 
However, CLAS may be comparably cost-effective by decreasing number and length 
of group meetings. Current studies are looking at the efficacy of a streamlined CLAS 
structure with reduced and centralized group sessions.
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OBJECTIVES: The increase in numbers of patients requiring oral anti-coagulation 
testing in outpatient clinics has focused attention on alternative flexible systems 
of anti-coagulation management. One option is pharmacist led patient self-test-
ing (PST) of international normalised ratio (INR) levels. PST has demonstrated 
improvements in anti-coagulation control, but its cost-effectiveness is inconclu-
sive. This study reports the first cost-effectiveness evaluation of a randomized con-
trolled trial of an automated direct-to-patient expert system, enabling remote and 
effective management of patients on oral anti-coagulation therapy. METHODS: We 
conducted an economic evaluation alongside a randomised controlled trial inves-
tigating a pharmacist led PST method. The primary outcome was to determine the 
cost effectiveness of PST in comparison with usual care (management in a hospital 
based anti-coagulation clinic). Long term anti-coagulation patients were recruited 
to a 6 month cross over study between PST and routine care in an anti-coagulation 
clinic. Economic evaluation was from the healthcare payer perspective. RESULTS: 
On a per patient basis over a 6 month period, PST resulted in an incremental 
cost of € 59·08 in comparison with routine care. Patients achieved a significantly 
higher time in therapeutic range (TTR) during the PST arm in comparison with 
routine care, (72 ± 19·7% vs. 59 ± 13·5%). Overall cost of managing a patient through 
pharmacist supervised PST for a 6 month period is € 226·45. Additional analysis 
of strategies from a societal perspective indicated that PST was the dominant 
strategy. CONCLUSIONS: Pharmacist led patient self-testing is a viable method 
of management. It provides significant increases in anti-coagulation control for 
a minimal increase in cost.
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OBJECTIVES: The National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) is the largest organized cancer screening program for low-income, unin-
sured or underinsured women in the United States. The program’s cost-effectiveness 
in delivering breast cancer screening services to the eligible women has not been 
quantified. To estimate the incremental cost-effectiveness of breast cancer screen-
ing in the NBCCEDP. METHODS: Building on an existing breast cancer screening 
simulation model developed by the Cancer Intervention and Surveillance Modeling 
Network, we incorporated data from the NBCCEDP on patient cohorts, screening 
frequency, and screening and diagnostic costs. We simulated breast cancer out-
comes, costs, and quality-adjusted life-years (QALYs) associated with three sce-
narios: breast cancer screening under the NBCCEDP, screening that would take 
place in the absence of the program, and a no screening scenario. We estimated 
incremental cost-effectiveness ratios (ICERs) and conducted sensitivity analyses. 
All costs were expressed in 2010 US dollars. Costs and QALYs were discounted at a 
3% rate. RESULTS: The estimated ICER for the program was $44,925 per QALY gained 
relative to no program and $43,956 per QALY relative to no screening. In the sensitiv-
ity analysis, ICER was more sensitive to screening costs and screening frequency. 
A lower screening cost reduces the estimated ICER to under $40,000 per QALY. On 
the other hand, a higher screening cost increases ICER. In probabilistic analyses, 
the mean ICER for the program compared with no program was $49,145 per QALY 
gained [95% confidence interval (CI): $20,893, $116,519 per QALY]. Relative to No 
Screening, the mean program ICER was $44,354 per QALY gained [95% CI: $22,937, 
$84,475 per QALY]. CONCLUSIONS: Breast cancer screening services in the NBCCEDP 
are on average cost-effective compared with screening outside the program or no 
screening. This finding supports the utility of the NBCCEDP program in serving the 
underserved populations.
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OBJECTIVES: Parenting programs are effective in reducing child conduct prob-
lems (CP) but there are no cost-effectiveness analyses (CEA) comparing different 
programs within the same RCT. This study aimed at conducting a CEA of an RCT 
where the group-based parenting programs: Comet, Incredible Years (IY), Cope and 
Connect, and bibliotherapy were compared to a waitlist control with a time horizon 
of 4 months from a government payer perspective targeting CP in children aged 
3-12 years. METHODS: The study samples consisted of 961 parents of 3-12 year-old 
children with CP, including 862 who started a program or reading a book, and 159 
in the waitlist. CP were measured by the Eyberg Child Behavior Inventory (ECBI). 
Effectiveness was expressed as the proportion of “recovered” cases of CP based on 
the Reliable Clinical Change Index. Intervention costs and parents’ time costs are 
reported. A CEA was performed comparing costs and effects between interventions 
that showed differences in outcomes and a cost-minimisation where outcomes were 
